Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs  

Hennigsdorf, January 11, 2022 – Pantherna Therapeutics today announces the successful completion of a follow-on financing round totaling EUR 4.0 Mio. led by existing investors Riesner Verwaltungs GmbH and High-Tech Gründerfonds. The proceeds of this round will be used to accelerate preclinical development activities for its lead program PAN004, an mRNA-based therapeutic for Acute Respiratory Distress Syndrome (ARDS).  

 

ARDS causes a life-threatening damage to the lungs induced by an excessive hyperinflammatory reaction of the lung tissue in response to bacterial and viral infections including SARS-CoV2 (COVID-19). No targeted therapy is available for this syndrome to prevent fluid retention and tissue damage to the lungs. Pantherna Therapeutics is developing a targeted therapy with a new mode of action by expressing a TIE-2 receptor agonist to restore endothelial barrier function. 

 

About Pantherna  
Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.   

 

Back